HemoBioTech Announces New Patent For Treating Acute Blood Loss

July 29, 2010

HemoBioTech (Pink Sheets:HMBT) announced the issuance of a new patent US 7,759,306 B2, "Methods of Treating Acute Blood Loss." HemoBioTech has an exclusive worldwide license from Texas Tech University to commercialize the technology. The new patent continues to May 16, 2026. The new patent involves HemoTech which induces the production of new red blood cells in the body. Uses for HemoTech could involve the treatment of acute blood loss and anemia in trauma, surgery, cancer, kidney disease and heart disease. The market for treatment of acute anemia is over $2 billion... read full article

You may also be interested in these articles:

home | featured services | faq | health news | contact

This information is not designed to replace a physician's independent judgment about the appropriateness or risks of a procedure for a given patient. Always consult your doctor about your medical conditions. FirstAndHealth.com does not provide medical advice, diagnosis or treatment. All materials were gathered from publicly available 3rd party resources and are NOT approved or reviewed by medical doctors.

Copyright © 2010. All rights reserved.
FirstAndHealth.com is owned and operated by Brightgeist Media, Inc.
Please read our privacy policy.